Cybin (HELP) News Today

Cybin Inc. (NASDAQ: HELP) has been moving higher, supported primarily by a major increase in TD Cowen’s valuation target and a bullish rating. The company remains unprofitable, but analysts’ longer-term forecasts suggest potential earnings growth if Cybin successfully advances its psychedelic-based treatments.

• Positive Sentiment: TD Cowen raised its price target for Cybin from $8 to $62—nearly eight times higher—and upgraded the stock to “buy.” The target implies substantial potential upside from recent trading levels, providing the main bullish catalyst for HELP. HELP Stock Jumps 6% After TD Cowen Hikes Target Nearly 8x To $62
• Positive Sentiment: HC Wainwright improved its estimates for several periods, including fiscal 2027 EPS to a loss of $2.78 from a loss of $2.96, fiscal 2029 EPS to a loss of $1.09 from a loss of $1.20, fiscal 2030 EPS to positive $0.62 from $0.36, and fiscal 2031 EPS to positive $3.78 from $3.23. These revisions indicate stronger expected profitability in the outer years.
• Positive Sentiment: HC Wainwright also raised its quarterly EPS forecasts for the second and third quarters of fiscal 2027 and modestly improved estimates for the fourth quarter of fiscal 2027 and first quarter of fiscal 2028.
• Neutral Sentiment: The analyst’s projections still show significant losses in the near and medium term, with estimated fiscal 2028 EPS of negative $2.19 and fiscal 2029 EPS of negative $1.09. The bullish case therefore depends heavily on successful development, regulatory progress and eventual commercialization of Cybin’s therapies.
• Negative Sentiment: HC Wainwright lowered several forecasts, including fiscal 2028 EPS to a loss of $2.19 from a loss of $2.09 and selected 2028 quarterly estimates. Cybin’s latest reported quarter also missed earnings expectations, highlighting continued execution and cash-burn risks.

Overall, the stock’s recent strength appears driven more by TD Cowen’s sharply higher target and improving long-term earnings outlook than by current fundamentals, which remain loss-making and highly dependent on clinical and regulatory milestones.